FDA declines to approve Summit's ivonescimab lung cancer drug
Investor's Business Daily reported that the FDA did not approve Summit Therapeutics' China-developed lung cancer drug ivonescimab, saying it failed to show a statistically significant survival benefit. A follow-up IBD post said Summit's stock crashed Monday after the FDA rejected the Merck-rivaling drug.
Why “Unverified”
- Reported by Investor's Business Daily alone, with no second source or primary confirmation yet
1 independent source group across 2 posts · evidence score 52/100. How labels work
What the sources claim
-
The FDA did not approve Summit Therapeutics' ivonescimab because it failed to show a statistically significant survival benefit.
“failed to show a statistically significant survival benefit”
Investor's Business Daily -
Summit Therapeutics' stock crashed Monday after the FDA rejected ivonescimab.
“Summit Therapeutics stock crashed Monday after the Food and Drug Administration rejected”
Investor's Business Daily
Sources
More in Stocks & Indices
Embed this page
Summary and claims extracted by AI with prompt analyze-story@5 on 2026-11-16 15:10 UTC. Labels are computed from the sources, not by the model.